From Nasdaq: 2024-06-30 13:40:39

Alnylam Pharmaceuticals stock (NASDAQ: ALNY) has surged by 60% in a week due to positive data from a late-stage trial for its cardiovascular drug, Amvuttra. The drug is already FDA-approved for certain conditions and has the potential to compete with Pfizer’s Vyndaqel. Analysts estimate peak sales to be $3.5-4 billion by 2032.

Despite significant recent growth, ALNY stock may have more room for growth, trading at a lower valuation multiple than its three-year average. Alnylam’s revenue has seen substantial growth, with estimates projecting further increases in the coming years. The recent positive developments around Amvuttra signal strong sales growth ahead, which has garnered investor interest.

In comparison to other companies, Alnylam has outperformed on key metrics like revenue growth and market share gains for its drugs. The recent boost in ALNY stock is reflective of positive investor sentiment, signaling potential for further growth. The company’s performance and current valuation align with forecasts made four years ago, indicating sustained growth potential.



Read more at Nasdaq: What’s Next For Alnylam Stock After A 60% Rise In A Week?